Victory Capital Management Inc. Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Victory Capital Management Inc. boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 19.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 303,556 shares of the company's stock after buying an additional 48,516 shares during the period. Victory Capital Management Inc. owned 0.24% of Vaxcyte worth $24,849,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PCVX. Whipplewood Advisors LLC acquired a new position in shares of Vaxcyte during the 4th quarter valued at about $28,000. Smartleaf Asset Management LLC boosted its holdings in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the last quarter. Meeder Asset Management Inc. grew its stake in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after buying an additional 635 shares during the period. Blue Trust Inc. increased its holdings in shares of Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after buying an additional 371 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new stake in shares of Vaxcyte during the 3rd quarter valued at approximately $92,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares of the company's stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,720,610.98. This represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,250 shares of company stock valued at $4,550,258. 3.10% of the stock is currently owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

PCVX has been the subject of several analyst reports. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of "Buy" and an average price target of $147.50.

Vaxcyte Stock Performance

Shares of PCVX traded up $1.35 during mid-day trading on Friday, hitting $74.37. 835,116 shares of the company's stock were exchanged, compared to its average volume of 1,180,935. The company has a market cap of $9.58 billion, a price-to-earnings ratio of -16.17 and a beta of 1.02. Vaxcyte, Inc. has a fifty-two week low of $58.10 and a fifty-two week high of $121.06. The stock's 50-day moving average is $82.45 and its 200-day moving average is $94.29.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.